Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
about
Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons.Protein phosphorylation in neurodegeneration: friend or foe?Complement-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction.Aged dominant negative p38α MAPK mice are resistant to age-dependent decline in adult-neurogenesis and context discrimination fear conditioning.Early Life Stress and Epigenetics in Late-onset Alzheimer's Dementia: A Systematic Review
P2860
Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimer's disease.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@en
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@nl
type
label
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@en
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@nl
prefLabel
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@en
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@nl
P2093
P2860
P1476
Structure- and ligand-based dr ...... ainst the Alzheimer's disease.
@en
P2093
Carlos Henrique Tomich de Paula da Silva
Carlton Anthony Taft
Flávio Roberto Pinsetta
P2860
P304
P356
10.1080/07391102.2013.803441
P577
2013-06-28T00:00:00Z